Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease,
despite the improvement of multi-modality treatment strategies, the prognosis of pancreatic …

Pancreatic adenocarcinoma is an aggressive disease marked by high rates of both local
and distant failure. In the minority of patients with potentially resectable disease, multimodal …

Pancreatic cancer (PDAC) is one of the most aggressive solid tumors and is showing
increasing incidence. The aim of our review is to provide practical help for all clinical …

Background There is accumulating evidence supporting the clinical use of circulating tumor
DNA (ctDNA) in solid tumors, especially in different types of gastrointestinal cancer. As such …

Death from pancreatic adenocarcinoma (PDAC) is predicted to surpass colorectal cancer to
become the second leading cause of cancer-related death by 2030. 1 The incidence of …

Pancreatic ductal adenocarcinoma (PDAC) ranks among the 15 most prevalent cancers
globally, characterized by aggressive growth and late-stage diagnosis. Advances in imaging …

Pancreatic cancer is a complex malignancy associated with poor prognosis and high
symptom burden. Optimal patient care relies on the integration of various sectors in the …

Pancreatic ductal adenocarcinoma (PDAC) remains a devastating diagnosis with significant
morbidity and poor survival. Pancreatic cancer is projected to be the second leading cause …

Abstract Background and Objectives Neoadjuvant chemotherapy (NAC) is becoming
favored for all pancreatic adenocarcinoma (PDAC). Patients with seemingly resectable …

Pancreatic ductal adenocarcinoma (PDAC), which is notorious for its aggressiveness and
poor prognosis, remains an area of great unmet medical need, with a 5-year survival rate of …